Skip to content

Clinical study of prostate cancer stratified precise treatment based on precise diagnosis of prostate cancer

Clinical study of prostate cancer stratified precise treatment based on precise diagnosis of prostate cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074697
Enrollment
Unknown
Registered
2023-08-14
Start date
2023-02-01
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Experimental group:Localized brachytherapy under the guidance of MRI and ultrasound
Control group:Radical brachytherapy guided by nuclear magnetic resonance ultrasound fusion for prostate tumor lesions

Sponsors

Urology Department of Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Low-risk prostate cancer defined by NCCN guidelines and medium-risk prostate cancer with good prognosis 2. MRI showed a single lesion and confirmed prostate cancer by biopsy 3. Gleason score of cancer is less than or equal to 7 points 4. TNM stage is less than or equal to T2b 5. Sign informed consent to understand the risks and benefits of local and radical treatment

Exclusion criteria

Exclusion criteria: 1. Received androgen deprivation treatment in the past 2. History of previous pelvic radiotherapy 3. There are contraindications to close treatment 4. Refuse to sign informed consent

Design outcomes

Primary

MeasureTime frame
Biochemical recurrence free survival rate;Blinical relapse-free survival rate;Proportion of patients transferred to radical treatment;

Secondary

MeasureTime frame
Rate of adverse events;

Countries

China

Contacts

Public ContactYan Weigang

Urology Department of Peking Union Medical College Hospital

pumchywg@sina.com+86 136 4132 7941

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026